---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269506"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:43:03.803398+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives

## Summary
- Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.
- Cash and investments $25.2M as of Sept 30, 2025, down from $51.3M at Dec 31, 2024.
- R&D expenses fell to $2.8M from $17.9M; G&A expenses $4.1M vs $7.6M year-over-year.
- Company continues to explore strategic alternatives to maximize stockholder value; engaged Cantor Fitzgerald.
- Phase 1 data for ALS candidate ATH-1105 showed favorable safety, dose-proportional PK, and CNS penetration.

## SEC filing metadata
- accession: 0001193125-25-269506
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/0001193125-25-269506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269506
- JSON: https://secwatch.observer/filing/0001193125-25-269506.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.